Fatty acid oxidation inhibitors in the treatment of stable angina

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.authorChong, Haemin
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház, Aneszteziológiai és Intenziv Therápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2022-01-19T12:21:28Z
dc.date.available2022-01-19T12:21:28Z
dc.date.created2021-08-30
dc.description.abstractRanolazine is a newer drug working as a partial fatty acid oxidase inhibitor, that will inhibit the late sodium currents of the cardiac myocytes and reduces the sodium and overall, calcium overload that occurs in ischemia. In turn, this results in ventricular and myocardial relaxation, aiding in perfusion and recovery. In establishing itself as a metabolic modulator, the hemodynamics of the myocardial are not altered to an extent that other therapeutic treatments pose. The following clinical trials support the positive efficacy in the use of Ranolazine as monotherapy or as adjuvant therapy in CSA. Continuous study will be useful in in investigating potential future applications in the treatment of CSA.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent31hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/328034
dc.language.isoenhu_HU
dc.subjectstable angina beta oxidation inhibitorshu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleFatty acid oxidation inhibitors in the treatment of stable anginahu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)